Posted by Michael Wonder on 03 Aug 2020
Slow start for infliximab biosimilars
3 August 2020 - Investigators speculate on why infliximab biosimilars don’t have a larger market share by now.
The uptake of infliximab biosimilars in the United States is slow but tracks closely to the experience in Europe, where after 2 years infliximab biosimilars assumed a large share of the market, according to a new study.
Infliximab biosimilar uptake has lagged filgrastim biosimilar uptake, and investigators theorised providers find it easier to prescribe a change of medicine in the case of filgrastim, which is for blood cell regeneration following radiotherapy, than for infliximab, which is for rheumatoid arthritis and related conditions. They said physicians are naturally more cautious about changing medicines for chronic conditions that are well controlled with the initial medication.
